Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 1369496-50-3 | MDL No. : | MFCD19689136 |
Formula : | C6H3NO3 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | YRLAJNQYJPKTAK-UHFFFAOYSA-N |
M.W : | 137.09 g/mol | Pubchem ID : | 18507598 |
Synonyms : |
|
Num. heavy atoms : | 10 |
Num. arom. heavy atoms : | 5 |
Fraction Csp3 : | 0.0 |
Num. rotatable bonds : | 1 |
Num. H-bond acceptors : | 4.0 |
Num. H-bond donors : | 1.0 |
Molar Refractivity : | 30.38 |
TPSA : | 74.23 Ų |
GI absorption : | High |
BBB permeant : | No |
P-gp substrate : | No |
CYP1A2 inhibitor : | No |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -6.73 cm/s |
Log Po/w (iLOGP) : | 0.9 |
Log Po/w (XLOGP3) : | 0.57 |
Log Po/w (WLOGP) : | 0.85 |
Log Po/w (MLOGP) : | -0.92 |
Log Po/w (SILICOS-IT) : | 0.62 |
Consensus Log Po/w : | 0.4 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 1.0 |
Bioavailability Score : | 0.56 |
Log S (ESOL) : | -1.35 |
Solubility : | 6.08 mg/ml ; 0.0444 mol/l |
Class : | Very soluble |
Log S (Ali) : | -1.7 |
Solubility : | 2.73 mg/ml ; 0.0199 mol/l |
Class : | Very soluble |
Log S (SILICOS-IT) : | -1.04 |
Solubility : | 12.5 mg/ml ; 0.091 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 2.6 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P280-P305+P351+P338-P310 | UN#: | N/A |
Hazard Statements: | H302-H315-H319-H332-H335 | Packing Group: | N/A |
GHS Pictogram: |
![]() |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
86.1% | With N-ethyl-N,N-diisopropylamine; HATU; In N,N-dimethyl-formamide; at 20.0℃; | To the mixture of 4-(4-methylpiperazin-1-yl)-2- (piperidin-1-yl)aniline (0.5 g, 1.82 mmol), <strong>[1369496-50-3]4-cyanofuran-2-carboxylic acid</strong> (0.3 g, 2.18 mmol), HATU (0.83 g, 2.18 mmol), in DMF (10 mL) was added DIPEA (0.63 mL, 3.64 mmol). The reaction mixture was stirred at room temperature overnight and then partitioned between EtOAc and brine. The organic layer was separated, dried over anhydrous MgSO4, filtered, and concentrated under a vacuum. The resulting residue was purified by silica gel column chromatography (CH2Cl2: MeOH = 9:1) to give 4-cyano-N-(4-(4-methylpiperazin-1-yl)-2-(piperidin-1-yl)phenyl)furan-2- carboxamide as a pale yellow solid (0.62 g, 86.1% yield).1H NMR (500 MHz, CDCl3) d 9.41 (s, 1H), 8.31 (d, J = 8.7 Hz, 1H), 8.03 (s, 1H), 7.33 (s, 1H), 6.78 (s, 1H), 6.72 (d, J = 8.8 Hz, 1H), 3.19 (s, 4H), 2.83 (s, 4H), 2.59 (s, 4H), 2.36 (s, 3H), 1.76 (s, 4H), 1.63 (s, 2H). |
[ 4412-96-8 ]
3-Methylfuran-2-carboxylic acid
Similarity: 0.80
[ 56172-36-2 ]
5-Hydroxybenzofuran-2-carboxylic acid
Similarity: 0.75
[ 212197-74-5 ]
5-Cyanofuran-2-carboxylic acid
Similarity: 0.74
[ 212197-74-5 ]
5-Cyanofuran-2-carboxylic acid
Similarity: 0.74
[ 173900-47-5 ]
4-Hydroxy-3-methoxy-5-methylbenzonitrile
Similarity: 0.65
[ 90178-72-6 ]
4-(3-Formylphenoxy)benzonitrile
Similarity: 0.64
[ 4412-96-8 ]
3-Methylfuran-2-carboxylic acid
Similarity: 0.80
[ 6141-57-7 ]
Methyl 3-methylfuran-2-carboxylate
Similarity: 0.76
[ 212197-74-5 ]
5-Cyanofuran-2-carboxylic acid
Similarity: 0.74
[ 13529-17-4 ]
5-Formylfuran-2-carboxylic acid
Similarity: 0.71
[ 6338-41-6 ]
5-Hydroxymethyl-2-furancarboxylic acid
Similarity: 0.71